| Revenue growth | Q2 -14.2% YoY, +12.9% QoQ; H1 -18.6% YoY |
|---|---|
| Margins | Adj EBITDA margin 9.6% vs 2.2% Q1, 23.2% Q2FY26; gross margin 70.8% |
| Order book | Multiple reload orders; Q3/Q4 order position improved materially |
| Demand visibility | Improved Q3/Q4 small-molecule reload orders; late-stage RFPs rising |
| Management confidence | Expects H2 stronger; no quantified guidance |
Growth
Q2 revenue -14.2% YoY, +12.9% QoQ; H1 revenue -18.6%. Sapala +33.6% Q2, +83.1% H1; Pharma CDMO -27.4% Q2.
Outlook
Management expects H2FY27 revenue and EBITDA to grow YoY and exceed H1. Capex for adjacencies and R&D to be announced.
Risks
Lower AgChem volumes, pricing pressure, gross margin down 377 bps YoY to 70.8%, API raw-material inflation, CDMO customer destocking.
Last quarter's promises, checked
Delivered
- Q2 sequential rise → rev +12.9% QoQ to INR 4,766 Mn (= BEAT)
- Sapala growth → Q2 +33.6% YoY, H1 +83.1% (= BEAT)
Partly delivered
- Q2 CDMO 'significantly better than Q1' → Pharma CDMO -27.4% YoY vs -38.7% Q1 (= PARTIAL)
Missed
- YoY comparability by end-H1 → Q2 -14.2%, H1 -18.6% (= MISS)
- INR 260 Cr restocking sized by Q2 call → not quantified (= MISS)
- FY27 margin near prior-year → Q2 adj EBITDA 9.6% vs Q2FY26 23.2% (= MISS)
Investor Presentation filed with NSE, NSE: COHANCE. Summary written with AI assistance from the document.
Cohance Lifesciences Ltd: key numbers
- Share price
- ₹433.00
- Market cap
- ₹16,566 Cr
- Revenue (annual)
- ₹2,269 Cr
- Net profit (annual)
- ₹179.2 Cr
- P/E (TTM)
- 155.9×Sector 42.0×
- Promoter holding
- 57.48%-0.01% QoQ
- FII holding
- 7.71%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Cohance Lifesciences Ltd
All →Cohance Lifesciences Management Change
Cohance Lifesciences appointed Kuber Jagdale as Executive Director for 60 months, effective 7 November 2026. He brings over three decades of pharmaceutical manufacturing and operations experience.
Cohance Lifesciences Earnings Call Transcript: Key Takeaways
Q2 revenue rose about 13% QoQ to ₹477 Cr and adjusted EBITDA reached about ₹46 Cr (~10% margin), but both remain below last year. H2 YoY growth is promised without figures, and FY27 specialty chemicals guidance was cut to decline.
Cohance Lifesciences Results Update
Cohance Lifesciences issued a press release on its unaudited Q2 and H1 FY27 results. It reported lower year-on-year revenue and an expected stronger second half.
Cohance Lifesciences Q2 FY27 Results: Net Profit ₹2.3 Cr, Down 96.5% YoY
Cohance Lifesciences Ltd reported revenue from operations of ₹476.6 Cr (-14.2% YoY) and net profit of ₹2.3 Cr (-96.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹2.3 Cr · -96.5% YoY
Cohance Lifesciences Adverse Business Impact
Cohance Lifesciences disclosed a TGPCB closure order halting manufacturing at its Suryapet site after an industrial accident. The financial impact cannot yet be quantified.
Cohance Lifesciences Board Meeting Date
Cohance Lifesciences will hold a board meeting on 6 November 2026 to approve Q2 and half-year results. The trading window stays closed until 9 November 2026.